News

• November 13, 2008

  Theratechnologies: Last patient treated in the extension phase of the confirmatory study testing tesamorelin in HIV-associated lipodystrophy More...

• November 6, 2008

  Theratechnologies presents additional results from its tesamorelin Phase 3 studies at the 10th International workshop on adverse drug reactions and lipodystrophy in HIV More...

• October 29, 2008

  Theratechnologies and EMD Serono Announce Collaboration and Licensing Agreement for Tesamorelin in the United States More...

• October 28, 2008

  Notice of Conference Call & Media Advisory More...

• October 9, 2008

  Theratechnologies Announces Financial Results and Highlights for the Third Quarter 2008 More...

• September 30, 2008

  Theratechnologies to present at BioContact Québec More...

• September 18, 2008

  Theratechnologies to present at UBS Global Life Sciences Conference More...

• September 2, 2008

  Theratechnologies announces publication in AIDS More...

• August 4, 2008

  Theratechnologies Reports on Positive Body Image Parameters at the International AIDS Conference More...

• July 31, 2008

  Theratechnologies Presents at Both BMO and Canaccord Adams Conferences and Comments on Strategic Review More...

• July 9, 2008

  Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2008 More...

• June 20, 2008

  Theratechnologies Comments on Current Market Activity More...

• June 18, 2008

  THERATECHNOLOGIES REPORTS POSITIVE 26-WEEK RESULTS FOR ITS SECOND TESAMORELIN PHASE 3 TRIAL More...

• June 17, 2008

  Notice of Conference Call & Media Advisory More...

• May 15, 2008

  Theratechnologies explores tesamorelin in growth hormone deficient abdominal obesity More...

• May 14, 2008

  Notice of Conference Call & Media Advisory More...

• May 12, 2008

  Theratechnologies and PDC Biotech GmbH sign license agreement for family of peptides for Preterm Labour and Primary Dysmenorrhea programs More...

• May 5, 2008

  Theratechnologies to present at BioFinance 2008 conference More...

• April 17, 2008

  Theratechnologies receives the 2008 Genesis Innovation Award More...

• April 14, 2008

  Theratechnologies: Last patient treated in the confirmatory study testing tesamorelin in HIV-associated lipodystrophy More...

• March 25, 2008

  Theratechnologies announces financial results and highlights of the first quarter 2008 More...

• March 24, 2008

  Theratechnologies: Annual General Meeting of Shareholders More...

• February 13, 2008

  Theratechnologies closes $29,750,000 financing More...

• February 6, 2008

  Theratechnologies presents additional results from its tesamorelin 52-week Phase 3 study at the Conference on Retroviruses and Opportunistic Infections More...

• January 31, 2008

  Theratechnologies announces common share offering More...

• January 29, 2008

  Theratechnologies announces review of strategic alternatives and filing of preliminary base shelf prospectus for up to $35 million equity financing More...

• January 23, 2008

  2007: A year of major accomplishments for Theratechnologies More...

• January 8, 2008

  Theratechnologies extends patent protection for tesamorelin in the treatment of HIV-associated lipodystrophy More...